Orthofix Medical (NASDAQ:OFIX) Major Shareholder Buys $169,270.56 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Engine Capital Management, Lp bought 13,061 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were purchased at an average price of $12.96 per share, for a total transaction of $169,270.56. Following the purchase, the insider owned 3,673,092 shares in the company, valued at $47,603,272.32. This trade represents a 0.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

• On Tuesday, February 24th, Engine Capital Management, Lp purchased 124,797 shares of Orthofix Medical stock. The stock was purchased at an average price of $12.55 per share, with a total value of $1,566,202.35.

Orthofix Medical Stock Up 2.7%

Shares of OFIX stock opened at $13.53 on Friday. The company has a market capitalization of $535.79 million, a price-to-earnings ratio of -5.78 and a beta of 0.78. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $18.66. The company’s fifty day moving average price is $14.08 and its 200-day moving average price is $14.71. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.45 and a quick ratio of 1.38.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.44 by ($0.50). The firm had revenue of $219.91 million during the quarter, compared to the consensus estimate of $218.72 million. Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%. Sell-side analysts expect that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Thursday, January 22nd. Barrington Research lowered their target price on shares of Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday. TD Cowen initiated coverage on shares of Orthofix Medical in a research note on Tuesday, January 27th. They set a “hold” rating and a $14.00 target price for the company. Finally, Canaccord Genuity Group reduced their price target on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Orthofix Medical presently has a consensus rating of “Hold” and an average price target of $18.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC raised its stake in Orthofix Medical by 99.0% during the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 955 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Orthofix Medical in the 3rd quarter worth about $30,000. Kestra Advisory Services LLC purchased a new stake in shares of Orthofix Medical during the 4th quarter valued at about $56,000. Strs Ohio purchased a new stake in shares of Orthofix Medical during the 1st quarter valued at about $150,000. Finally, Mackenzie Financial Corp bought a new position in shares of Orthofix Medical in the 3rd quarter valued at about $148,000. 89.76% of the stock is owned by hedge funds and other institutional investors.

Orthofix Medical News Summary

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) bought shares in two recent transactions — ~124,797 shares at ~$12.55 on Feb. 24 and an additional 13,061 shares at ~$12.96 on Feb. 25 — increasing its stake and signaling confidence from a large institutional holder. Engine Capital purchases OFIX shares
• Neutral Sentiment: Analysts trimmed price targets but kept several constructive ratings: Canaccord cut its target from $24 to $20 (still a “buy”) and others reduced targets modestly; consensus remains mixed (roughly a mid‑teens/$18-ish average target). This lowers upside expectations but does not indicate a broad teardown of the bull case. Analyst notes and price-target changes
• Negative Sentiment: Q4 results missed on EPS: reported ($0.06) vs. $0.44 expected; revenue was roughly in line but margins and ROE were negative — the EPS shortfall triggered investor selling and increased near-term skepticism. Shares down after earnings miss
• Negative Sentiment: Management flagged margin delays and issued revised 2026 guidance that shifts the narrative toward execution risk; until margin recovery and guidance clarity appear, the stock faces headwinds. Narrative shifting: margin delays and guidance

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.